Basic Search
|
Summaries
|
Advanced Search
Violation Tracker UK Individual Case
Company: Auden Mckenzie and Actavis UK
Current Parent Company:
Intas Pharmaceuticals Ltd.
Parent at the Time of the Penalty Announcement: Intas Pharmaceuticals Ltd.
Recap of Ownership Changes: In 2015 Auden McKenzie was acquired by Actavis PLC, which sold its generics business in 2016 to Teva Pharmaceuticals, which sold its UK generics business to Accord Healthcare, a subsidiary of Intas Pharmaceuticals, in 2017.
Penalty: £130,000,000
Year: 2023
Date: 18 September, 2023
Offence Group: competition-related offences
Offence Type: price-fixing or anti-competitive practices
Violation Description: The Competition Appeal Tribunal upheld a finding by the Competition and Markets Authority that Auden/Actavis UK abused a dominant market position to increase the price of hydrocortisone tablets over a decade by over 10,000%, imposing a fine of about £130 million.
Agency: Competition and Markets Authority
HQ Country of Parent: India
Ownership Structure of Parent: privately held
Major Industry of Parent: pharmaceuticals
Specific Industry of Parent: pharmaceuticals
Source of Data:
(click here)
